SHANGHAI, China--(BUSINESS WIRE)--EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce that the company will present the first-in-human results for EMB-02 as a poster display at the 2023 European Society for Medical Oncology (ESMO) Congress on October 23 (local time). This poster will feature initial safety, efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) data from the EMB-02 Phase I dose escalation study in advanced solid tumors (NCT04618393). The presentation details are as follows:
Title: Preliminary Phase I Results from a First-in-Human Study of EMB-02, a PD-1xLAG-3 Bispecific Antibody, in Patients (pts) with Advanced Solid Tumors
Presentation number: 1028P
EMB-02 is a bispecific antibody based on EpimAb’s proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) technology, which generates bispecific molecules with superior properties. The EMB-02 bispecific antibody targets two checkpoint proteins, PD-1 and LAG-3, and restores effector T cell function through robust inhibition and degradation of the target proteins in the tumor microenvironment. In addition, it has shown strong anti-tumor efficacy in in vivo tumor models resistant to standard anti-PD-1 monotherapies.
Dr. Chengbin Wu, Founder and CEO of EpimAb commented, “The ESMO Congress is one of the premier global oncology conferences and we look forward to sharing the detailed EMB-02 data with key stakeholders, including clinicians, researchers, patient advocates, and other health industry representatives, at this event.”
About EpimAb Biotherapeutics
EpimAb Biotherapeutics is a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies. Utilizing our broad range of in-house research and technology capabilities, including the proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms, EpimAb is generating and globally advancing a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. For further information, please visit: www.epimab.com